

Table of Contents

Abbreviations.....	1
1 Introduction.....	2
1.1 Cardiorenal syndrome.....	2
1.2 Cardiovascular diseases.....	2
1.2.1 Renin-angiotensin-aldosterone system.....	3
1.2.2 Post-translational modifications of angiotensin II	3
1.2.3 Hypertension	6
1.3 Renal diseases.....	6
1.3.1 Acute kidney injury	6
1.3.2 Pathophysiology of acute kidney injury.....	7
1.3.3 Biomarkers of acute kidney injury	8
1.3.4 <i>In vivo</i> models in acute kidney injury.....	9
1.4 Techniques for isolation and identification of novel biomarkers and treatment candidates.....	10
1.4.1 Chromatography.....	10
1.4.2 Mass Spectrometry.....	10
1.4.2.1 Matrix-assisted laser desorption/ionisation	10
1.4.2.2 Electrospray ionisation.....	11
1.4.2.3 Time-of-flight analyser	11
1.4.2.4 Quadrupole mass analyser.....	11
1.4.2.5 Tandem mass spectrometry	12
1.4.3 Mass spectrometry imaging.....	12
2 Objectives and aims of the thesis.....	14
3 Material and Methods	15
3.1 Methods used for the isolation and identification of novel treatment candidates for hypertensive patients	15
3.1.1 Reagents and chemicals	15
3.1.2 Synthesis of pyruvamide-peptides	15
3.1.3 Matrix-assisted laser desorption/ionisation mass spectrometry.....	15
3.1.4 Quantification of pyruvamide-peptides.....	16
3.1.5 Human aortic vascular smooth muscle cells culture.....	16
3.1.6 Measurement of calcium ion entry	16

Table of Contents

3.1.7	Radioligand binding assay	17
3.1.8	Isolated perfused rat kidney	17
3.1.9	Blood pressure measurement in <i>in vivo</i> experiments	18
3.1.10	Parameters in rat urine and plasma	18
3.1.11	Histological analysis	18
3.1.12	Purification of pyruvamide-Ang II from human plasma	19
3.1.13	Liquid chromatography-mass spectrometry	20
3.1.14	Ethical considerations	21
3.1.15	Statistics	21
3.2	Methods used for the isolation and identification of novel biomarkers in the context of acute kidney injury	22
3.2.1	Reagents and chemicals	22
3.2.2	PEC-rtTA mouse experiments	22
3.2.3	Mouse kidney extraction	22
3.2.4	Mouse kidney cell isolation for proteomics	23
3.2.5	Human plasma isolation and sample preparation for proteomics	23
3.2.6	Matrix-assisted laser desorption/ionisation mass spectrometry	23
3.2.7	Quantification of protein kinase X-linked	24
3.2.8	MALDI mass spectrometry imaging	24
3.2.9	Ethical considerations	25
3.2.10	Statistics	25
4	Results	26
4.1	A novel treatment candidate for hypertensive patients: Pyridoxal-5'- phosphate	26
4.1.1	<i>In vitro</i> synthesis of pyruvamide-Ang II by incubation of angiotensin II and pyridoxal-5'-phosphate	26
4.1.2	Incubation of angiotensin peptides with pyridoxal-5'-phosphate	28
4.1.3	Incubation of cortistatin-17 (1-8) with pyridoxal-5'-phosphate	30
4.1.4	Binding of pyruvamide-Ang II to the angiotensin II type 1 receptor	32
4.1.5	<i>Ex vivo</i> effect of pyruvamide-Ang II on perfusion pressure in an isolated perfused rat kidney	34
4.1.6	Effect of pyridoxal-5'-phosphate on blood pressure <i>in vivo</i> in spontaneously hypertensive rats	37

Table of Contents

4.1.7	Effect of pyridoxal-5'-phosphate on blood pressure <i>in vivo</i> in Wistar Kyoto rats	40
4.1.8	Level of pyruvamide-angiotensin II in human plasma	42
4.2	A novel biomarker in the context of acute kidney injury: Protein kinase X-linked	43
4.2.1	Protein kinase X-linked in mouse kidneys after acute kidney injury.....	43
4.2.2	Protein kinase X-linked in human plasma after acute kidney injury.....	45
5	Discussion	48
5.1	A novel treatment candidate for hypertensive patients: Pyridoxal-5'-phosphate	48
5.2	A novel biomarker in the context of acute kidney injury: Protein kinase X-linked	52
6	Summary	56
7	References	57
8	List of tables	64
9	List of figures	65
10	List of own publications	72
11	Conferences and Workshops	74
12	Acknowledgement	77
13	Erklärung § 5 Abs. 1 zur Datenaufbewahrung	79
14	Eidesstattliche Erklärung gemäß § 5 Abs. (1) und § 11 Abs. (3) 12. der Promotionsordnung	80
15	Curriculum Vitae	81